Chiome Bioscience's share price hit the daily limit-up on 4 September, as short-term funds flowed in following the launch of joint research with FRONTEO. Moves to track Japanese stocks centered on the theme of collaboration between AI drug discovery and antibody therapeutics were reported.
On 4 September 2026, Chiome Bioscience's share price rose ¥30 from the previous day to ¥112, hitting the daily limit-up, while trading volume exceeded 18.04 million shares. The catalyst was reportedly joint research combining FRONTEO's AI drug discovery support technology, Drug Discovery AI Factory, with Chiome's bispecific antibody generation technology, DoppeLib.
The objective of the joint research is to examine multiple drug discovery themes and generate bispecific antibody drug candidates by fiscal 2027. By connecting AI-based target discovery with antibody design, the companies aim to generate projects at each stage of the drug discovery value chain.
Financially, Chiome's revenue for the first half of 2026 was ¥273.65 million, while its operating loss was ¥479.71 million. Its drug discovery support business is securing a profit, but research and development expenses for its proprietary drug discovery operations remain substantial. The potential to secure contractual upfront payments and milestone payments is also noted.
In addition to FRONTEO, the discussion covers the use of AI in the antibody therapeutics sector and the formation of large markets, including antibody design using Chugai Pharmaceutical's MALEXA and growth in sales of Daiichi Sankyo's Enhertu product. Several companies are identified as stocks to watch in the AI drug discovery and antibody therapeutics space.